|
from the imgn website
...
We’re delighted with Genentech’s progress with T-DM1. In July 2007, they began Phase II testing of the compound in patients with HER2-overexpressing metastatic breast cancer that’s progressed during prior treatment with a HER2-directed therapy. Genentech already has over 30 sites enrolling patients in the study listed on clinicaltrials.gov and plans to include 100 patients. They’re also continuing to report new Phase I data. At the American Society of Clinical Oncology (ASCO) annual meeting in June they reported that 3 of the 9 patients treated with T-DM1 at the maximum tolerated dose (MTD) had an objective response – even though all of these patients had cancer that progressed on treatment with Herceptin® plus chemotherapy. By the time of the European Cancer Conference (ECCO) meeting in September, 15 patients had received T-DM1 at its MTD, and 5 of these patients have had an objective response. Phase I findings also are scheduled for presentation at this year’s San Antonio Breast Cancer symposium, to be held about six weeks from now.
|